Experimental drugs to prevent heart disease, flakersen from Novartis and ziltivkemab from Novo Nordisk were no more effective than placebo, writes the New York Times. Clinical trials, one of which included 6,376 patients, showed that the drugs do not reduce the risk of heart attacks and strokes. The results of the study were published in the New England Journal of Medicine and, according to cardiologists, call into question the assumptions on which the development of these drugs was based.